Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany

Research output: Contribution to journalArticleResearchpeer review

Authors

  • Uwe Siebert
  • Gaby Sroczynski
  • Jürgen Wasem
  • Wolfgang Greiner
  • Ulrike Ravens-Sieberer
  • Pamela Aidelsburger
  • Bärbel M. Kurth
  • Monika Bullinger
  • J. Matthias Graf Von Der Schulenburg
  • John B. Wong
  • Siegbert Rossol

External Research Organisations

  • Harvard University
  • Ludwig-Maximilians-Universität München (LMU)
  • University of Duisburg-Essen
  • Robert Koch Institute (RKI)
  • Universität Hamburg
  • Tufts University
  • General Hospital Rüsselsheim
View graph of relations

Details

Original languageEnglish
Pages (from-to)112-123
Number of pages12
JournalEuropean Journal of Health Economics
Volume6
Issue number2
Early online date18 May 2005
Publication statusPublished - Jun 2005

Abstract

The objective of this study was to translate and apply a decision-analytic model for chronic hepatitis C (CHC) to the German health care context using competence network collaboration. The German Hepatitis C Model (GEHMO) competence network used a systematic multistep approach to identify and transfer a high quality Markov model for CHC to the German health care context. GEHMO was used to project lifetime clinical and economic outcomes and to determine the cost-effectiveness of initial antiviral therapy with interferon α-2b plus ribavirin from a societal perspective. In 40-year-old patients combination therapy for 24 and 48 weeks increased life expectancy by 1.6 and 2.3 years, respectively, compared with interferon alone for 48 weeks. The discounted incremental cost-utility ratios (ICUR) for combination therapy were €5,500 per quality-adjusted life-year gained (QALY) for 24 weeks and €6,800/QALY for 48 weeks of treatment. ICUR was €9,800/QALY for moving from 24 to 48 weeks of treatment. Combination therapy remained cost-effective in sensitivity analyses. In conclusion, combination therapy with interferon α-2b and ribavirin is effective and cost-effective compared with other well-accepted medical treatments. Competence network collaboration and decision modeling provide a useful and efficient approach to combine evidence from international studies with country-specific parameters.

Keywords

    Chronic hepatitis C, Competence network collaboration, Cost-effectiveness analysis, Interferon α-2b, Ribavirin

ASJC Scopus subject areas

Sustainable Development Goals

Cite this

Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. / Siebert, Uwe; Sroczynski, Gaby; Wasem, Jürgen et al.
In: European Journal of Health Economics, Vol. 6, No. 2, 06.2005, p. 112-123.

Research output: Contribution to journalArticleResearchpeer review

Siebert, U, Sroczynski, G, Wasem, J, Greiner, W, Ravens-Sieberer, U, Aidelsburger, P, Kurth, BM, Bullinger, M, Graf Von Der Schulenburg, JM, Wong, JB & Rossol, S 2005, 'Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany', European Journal of Health Economics, vol. 6, no. 2, pp. 112-123. https://doi.org/10.1007/s10198-005-0280-7
Siebert, U., Sroczynski, G., Wasem, J., Greiner, W., Ravens-Sieberer, U., Aidelsburger, P., Kurth, B. M., Bullinger, M., Graf Von Der Schulenburg, J. M., Wong, J. B., & Rossol, S. (2005). Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. European Journal of Health Economics, 6(2), 112-123. https://doi.org/10.1007/s10198-005-0280-7
Siebert U, Sroczynski G, Wasem J, Greiner W, Ravens-Sieberer U, Aidelsburger P et al. Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. European Journal of Health Economics. 2005 Jun;6(2):112-123. Epub 2005 May 18. doi: 10.1007/s10198-005-0280-7
Download
@article{0faa3a5b5598472490d455217d15461f,
title = "Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany",
abstract = "The objective of this study was to translate and apply a decision-analytic model for chronic hepatitis C (CHC) to the German health care context using competence network collaboration. The German Hepatitis C Model (GEHMO) competence network used a systematic multistep approach to identify and transfer a high quality Markov model for CHC to the German health care context. GEHMO was used to project lifetime clinical and economic outcomes and to determine the cost-effectiveness of initial antiviral therapy with interferon α-2b plus ribavirin from a societal perspective. In 40-year-old patients combination therapy for 24 and 48 weeks increased life expectancy by 1.6 and 2.3 years, respectively, compared with interferon alone for 48 weeks. The discounted incremental cost-utility ratios (ICUR) for combination therapy were €5,500 per quality-adjusted life-year gained (QALY) for 24 weeks and €6,800/QALY for 48 weeks of treatment. ICUR was €9,800/QALY for moving from 24 to 48 weeks of treatment. Combination therapy remained cost-effective in sensitivity analyses. In conclusion, combination therapy with interferon α-2b and ribavirin is effective and cost-effective compared with other well-accepted medical treatments. Competence network collaboration and decision modeling provide a useful and efficient approach to combine evidence from international studies with country-specific parameters.",
keywords = "Chronic hepatitis C, Competence network collaboration, Cost-effectiveness analysis, Interferon α-2b, Ribavirin",
author = "Uwe Siebert and Gaby Sroczynski and J{\"u}rgen Wasem and Wolfgang Greiner and Ulrike Ravens-Sieberer and Pamela Aidelsburger and Kurth, {B{\"a}rbel M.} and Monika Bullinger and {Graf Von Der Schulenburg}, {J. Matthias} and Wong, {John B.} and Siegbert Rossol",
year = "2005",
month = jun,
doi = "10.1007/s10198-005-0280-7",
language = "English",
volume = "6",
pages = "112--123",
journal = "European Journal of Health Economics",
issn = "1618-7598",
publisher = "Springer Verlag",
number = "2",

}

Download

TY - JOUR

T1 - Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany

AU - Siebert, Uwe

AU - Sroczynski, Gaby

AU - Wasem, Jürgen

AU - Greiner, Wolfgang

AU - Ravens-Sieberer, Ulrike

AU - Aidelsburger, Pamela

AU - Kurth, Bärbel M.

AU - Bullinger, Monika

AU - Graf Von Der Schulenburg, J. Matthias

AU - Wong, John B.

AU - Rossol, Siegbert

PY - 2005/6

Y1 - 2005/6

N2 - The objective of this study was to translate and apply a decision-analytic model for chronic hepatitis C (CHC) to the German health care context using competence network collaboration. The German Hepatitis C Model (GEHMO) competence network used a systematic multistep approach to identify and transfer a high quality Markov model for CHC to the German health care context. GEHMO was used to project lifetime clinical and economic outcomes and to determine the cost-effectiveness of initial antiviral therapy with interferon α-2b plus ribavirin from a societal perspective. In 40-year-old patients combination therapy for 24 and 48 weeks increased life expectancy by 1.6 and 2.3 years, respectively, compared with interferon alone for 48 weeks. The discounted incremental cost-utility ratios (ICUR) for combination therapy were €5,500 per quality-adjusted life-year gained (QALY) for 24 weeks and €6,800/QALY for 48 weeks of treatment. ICUR was €9,800/QALY for moving from 24 to 48 weeks of treatment. Combination therapy remained cost-effective in sensitivity analyses. In conclusion, combination therapy with interferon α-2b and ribavirin is effective and cost-effective compared with other well-accepted medical treatments. Competence network collaboration and decision modeling provide a useful and efficient approach to combine evidence from international studies with country-specific parameters.

AB - The objective of this study was to translate and apply a decision-analytic model for chronic hepatitis C (CHC) to the German health care context using competence network collaboration. The German Hepatitis C Model (GEHMO) competence network used a systematic multistep approach to identify and transfer a high quality Markov model for CHC to the German health care context. GEHMO was used to project lifetime clinical and economic outcomes and to determine the cost-effectiveness of initial antiviral therapy with interferon α-2b plus ribavirin from a societal perspective. In 40-year-old patients combination therapy for 24 and 48 weeks increased life expectancy by 1.6 and 2.3 years, respectively, compared with interferon alone for 48 weeks. The discounted incremental cost-utility ratios (ICUR) for combination therapy were €5,500 per quality-adjusted life-year gained (QALY) for 24 weeks and €6,800/QALY for 48 weeks of treatment. ICUR was €9,800/QALY for moving from 24 to 48 weeks of treatment. Combination therapy remained cost-effective in sensitivity analyses. In conclusion, combination therapy with interferon α-2b and ribavirin is effective and cost-effective compared with other well-accepted medical treatments. Competence network collaboration and decision modeling provide a useful and efficient approach to combine evidence from international studies with country-specific parameters.

KW - Chronic hepatitis C

KW - Competence network collaboration

KW - Cost-effectiveness analysis

KW - Interferon α-2b

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=21344473696&partnerID=8YFLogxK

U2 - 10.1007/s10198-005-0280-7

DO - 10.1007/s10198-005-0280-7

M3 - Article

C2 - 15902546

AN - SCOPUS:21344473696

VL - 6

SP - 112

EP - 123

JO - European Journal of Health Economics

JF - European Journal of Health Economics

SN - 1618-7598

IS - 2

ER -